Editas Medicine: Bruce Eaton, Gad Berdugo
Bruce Eaton has been promoted to executive VP and chief business officer of genome editing company Editas Medicine. He is replacing Gad Berdugo as chief business officer, who has stepped down and is leaving the company. Eaton has worked with Editas since 2015, first as a consultant and later as a research collaborator, before joining the firm in 2018 as senior VP of chemistry and site head for Boulder after the firm acquired assets from i2 Pharmaceuticals, where Eaton was founder and CEO. Before that, he was chief operating officer of SomaLogic, and prior to that, VP of NexaGen. He holds a PhD in chemistry from the University of California, Berkeley, and BS degrees in chemistry and biology from the University of Oregon.